Biotroy Therapeutics was proudly listed in the 'Top 100 Chinese healthcare Front-Runners for 2023’

On October 16, the 2023 Shanghai International Biomedical Industry Week (IBIWS) was inaugurated at the Zhangjiang Science Hall. During IBIWS, the list of Top 100 Chinese healthcare Front-Runners for 2023 was released, and Biotroy Therapeutics was proudly listed in the 'Top 100 Chinese healthcare Front-Runners for 2023’.

This list is jointly selected by the Shanghai Biomedical Industry Promotion Center, PricewaterhouseCoopers, Shanghai Science and Innovation Group, and First Finance and other institutions. It focuses on non-publicly listed companies in the biomedical field, emphasizing value discovery and ecological construction. The evaluation is made after comprehensively considering factors like the company's valuation, growth potential, and innovation capabilities.


BioTroy Therapeutics is a company engaged in the research and development of new tumor treatment targets and drugs. Established in Shanghai in 2020, it has completed financing of over 150 million RMB. BioTroy Therapeutics has established multiple research platforms including BioTroy Engine for tumor multi-omics analysis, receptor-ligand discovery, target signal transduction pathway research, antibody discovery and engineering, in vivo pharmacodynamics and translational medicine in large animals, biomarkers, and precision medicine. The company is committed to 'from 0 to 1' original target discovery and global intellectual property layout. It advances 'first in class' new drug development based on solid scientific research data and cutting-edge translational medicine concepts. The company's main pipeline focuses on tumors that are unresponsive to PD-1/PD-L1 inhibitors, the first self-developed, novel-targeted anti-tumor drug has been approved for an Investigational New Drug (IND) application in the United States, officially entering the clinical development stage.